Anivive Licenses Novel Canine Cancer Therapeutic to Expand Sales and Accelerate Pipeline

LONG BEACH, Calif.: LONG BEACH, Calif., Jan. 12, 2022 /PRNewswire/ -- Anivive Lifesciences, a pet health technology company dedicated to solving unmet needs in the veterinary community, announces that Dechra Pharmaceuticals PLC (Dechra) has acquired the rights to Laverdia™-CA1 (verdinexor), a novel treatment for canine lymphoma. Anivive announces that Dechra...

Click to view original post